Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-04-25
2006-04-25
Minnifield, Nita (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S070210, C435S006120, C435S325000, C435S252300, C536S023500
Reexamination Certificate
active
07033774
ABSTRACT:
Polyclonal antibodies can be produced that reacts with recombinant EPO and its degradation products but not with native EPO. This antibody precipitation can be used to identify those glycopeptides that are uniquely reactive. These glycopeptides can be produced on preparative scale and used in the production of monoclonal antibodies which are screened against the original EPO and glycopeptides to select antibodies reactive to the specific glycopeptides an recombinant EPO but not to native human EPO. The monoclonal antibodies so selected are incorporated in a conventional ELISA and used to monitor urine and other bodily samples taken from athletes, either human or animal, and patients for presence and level of recombinant peptides or proteins. Alternatively, the polyclonal antibody can be used directly to produce ELISA tests.
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 5411864 (1995-05-01), Anicetti et al.
patent: 5541158 (1996-07-01), Vance et al.
patent: 5550155 (1996-08-01), Kashem et al.
patent: 5798216 (1998-08-01), Ruggeri et al.
patent: 5858752 (1999-01-01), Seed et al.
patent: 6573055 (2003-06-01), Murray
patent: 6596849 (2003-07-01), Roffler et al.
patent: 6821742 (2004-11-01), Lingappa et al.
patent: 0747705 (1996-12-01), None
Leonard, CK et al, (The Journal of Biological Chemistry(, 1990, vol. 260(18), pp. 10373-10382.
Fenquillet, Emmanuel et al (1996), pp. 224-231, Virology, vol. 218, Biological properties of recombinant HIV envelope synthesized in CHO glycosylation mutant cell lines.
Spellman, MW et al, The Journal of Biological chemistry, Vol264(24)1989,pp. 14100-14111.
Chen, W et al, Molecular and cellular endocrinology, Jul. 1992, vol. 86(1-2), pp. 57-66.
Shotton, C et al, Journal of Virology, Jan. 1995, vol. 69(1), apges 222-230.
Noguchi, A et al, Journal of Biochemistry, vol. 117, pp. 59-62, 1995.
Souillard, A et al, British journal of clinical pharmacology , vol. 42(3),pp. 355-364, Sep. 1996.
Watson et al, Glycobiology, 1994, vol. 4(2) pp. 227-237.
Redlich, PN et al, Journal of Immunology, Sep. 15, 1989, vol. 143(6), pp. 1887-1893, Analysis of antigenic dominas on natural and recombinant human IFN-beta by the inhibition of biological activities with monoclonal antibodies.
Wu, Z et al, Journal of Virology, vol. 69(4), pp. 2271-2278, Apr. 1995, Characterization of Neutralization Epitopes in the V2 region of Human immunodeficiency Virus Type I gp120: Role of Glycosylation in the Correct Folding of the V1/V2 Domain.
Elliott, Steve et al, Blood, vol. 87(7) Apr. 1, 1996, pp. 2714-2722, Isolation and Characterization of conformation sensitive antierythropoietin monoclonal antibodies: Effect of disulfide bonds and carbohydrate on Recom. human erythropoietin structure.
Fibi, MR et al, Blood, vol. 81(3), Feb. 1, 1993, pp. 670-675, Human erythropoietin-specific sites of monoclonal antibody mediated neutralization.
Knight, Pamela, “The Carbohydrate Frontier,” BIO/TECHNOLOGY, 791):35-40, Jan. 1989.
Seaver, Sally, “Monoclonal Antibodies in Industry: More Difficult Than Orginally Thought,” Genetic Engineering News, 14(14):10 and 21, Aug. 1994.
Seiver, E. Date eta l., “Monoclonal Antibodies in Clinical Immunology,” Clinical Chemistry, 27(11):1979-1806. Nov. 1981.
“Comparitive Study fo the Asparagine-linked Sugar Chains of Human Erythropoletins Purified from Unrine and the Culture Medium of Recombinant Chinese Hamster Ovary Cells,” Makoto Takeuchi, et al.,The Journal of Biological Chemistry, vol. 263, No. 8, issue Mar. 15, pp. 3657-3663, 1998.
“Compartive Structural Study of N-Linked Oligosaccharides of Urinary and Recombinant Erythropoietins,” Eisuke Tsuda, eta l.,Biochemistry, vol. 27, pp. 5646-5654, 1988.
“Structures and Functional Roles of the Sugar Chains of Human Erythropoietins,” Makoto Takeuchi, et al.,Glycobiology, vol. 1, No. 4, pp. 337-346, 1991.
Microheterogeneity of Erythropoietin Carbohydrate Structure, Robert S. Rush, et al.,Analytical Chemistry, vol. 67, No. 8, pp. 1442-1452, 1995.
“Glyosylation Engineering,” Pamela Stanley,Glycobiology, vol. 2, No. 2, pp. 99-107, 1992.
Glycosylation of Recombinant Protein Therapeutics: Control and Functional Implications, Dale A. Cumming,Glycobiology, vol. 1, No. 2, pp. 115-130, 1991.
“Invited Commentary,” roger A. Laine,Glyco-Forum Section, Depts. Of Biochemistry and Chemistry, Louisiana State University and the Louisiana Agricultural Center, Baton Rouge, LA 70803 USA, pp. 759-767.
Glycozyme, Inc.
Minnifield Nita
Portner Ginny Allen
LandOfFree
Determination of recombinant glycosylated proteins and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Determination of recombinant glycosylated proteins and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Determination of recombinant glycosylated proteins and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3582172